Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single Center, Open-Label, Randomized, Sequential Dose-Ascending Cross-Over Study to Evaluate the Pharmacokinetics and Tolerability of CTP-298 Amorphous Dispersion (450 mg, 550 mg, and 650 mg) at Steady State Compared to Atazanavir (300 mg) Coadministered With Ritonavir (100 mg) at Steady State in Healthy Male Adults

Next Previous
X
Search
Trial Profile

A Phase 1 Single Center, Open-Label, Randomized, Sequential Dose-Ascending Cross-Over Study to Evaluate the Pharmacokinetics and Tolerability of CTP-298 Amorphous Dispersion (450 mg, 550 mg, and 650 mg) at Steady State Compared to Atazanavir (300 mg) Coadministered With Ritonavir (100 mg) at Steady State in Healthy Male Adults

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTP 298 (Primary) ; Atazanavir/ritonavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors Concert Pharmaceuticals

    • Most Recent Events

    • 27 Jun 2013 Status changed from not yet recruiting to discontinued, based on the June 2013 product pipeline of Concert Pharmaceuticals. It appears that the development of this agent has been discontinued.
    • 15 Oct 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top